

TRADEMARK ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	MERGER		
EFFECTIVE DATE:	12/30/2005		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Sirius Laboratories, Inc.		02/27/2006	CORPORATION: ILLINOIS
RECEIVING PARTY DATA			
Name:	DUSA Pharmaceuticals, Inc.		
Street Address:	25 Upton Drive		
City:	Wilmington		
State/Country:	MASSACHUSETTS		
Postal Code:	01887		
Entity Type:	CORPORATION: NEW JERSEY		
PROPERTY NUMBERS Total: 23			
Property Type	Number	Word Mark	
Registration Number:	2961496	AVAR CLEANSER	
Registration Number:	2978865	AVAR GREEN	
Registration Number:	2974225	AVAR-E	
Registration Number:	2962635	AVAR-E GREEN	
Serial Number:	78734850	BACNE	
Serial Number:	78734855	BACNEPAC	
Serial Number:	78734843	BACPAC	
Serial Number:	78440569	BENNIC	
Serial Number:	78734830	BENZOBAC	
Serial Number:	78734820	CLINDABAC	
Serial Number:	78734867	EASYREACH	
Serial Number:	78734864	EXTENDERM	
Serial Number:	78734848	BPOBAC	

OP \$590.00 2961496

900044753

TRADEMARK
REEL: 003273 FRAME: 0809

Serial Number:	78108825	ATOPLEX
Serial Number:	78734869	REACHEASE
Serial Number:	78734838	TRETIBAC
Registration Number:	1419732	METED
Registration Number:	2592990	NICOMIDE
Registration Number:	2760258	PSORACAP
Registration Number:	2780636	PSORATEC
Registration Number:	2817708	SIRIUS LABORATORIES, INC.
Registration Number:	2990233	AVAR
Registration Number:	2982079	NICOMIDE-T

CORRESPONDENCE DATA

Fax Number: (215)851-8100

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 215-851-8100

Email: philpdocketing@reedsmith.com

Correspondent Name: Edward F. Behm, Jr.

Address Line 1: P.O. Box 7990

Address Line 2: Intellectual Property

Address Line 4: Philadelphia, PENNSYLVANIA 19101

ATTORNEY DOCKET NUMBER:	877888.20025
NAME OF SUBMITTER:	Edward F. Behm, Jr.
Signature:	/Edward F. Behm, Jr./
Date:	03/21/2006

Total Attachments: 7

source=SIRIUS#page1.tif

source=SIRIUS#page2.tif

source=SIRIUS#page3.tif

source=SIRIUS#page4.tif

source=SIRIUS#page5.tif

source=SIRIUS#page6.tif

source=SIRIUS#page7.tif

ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS

THIS ASSIGNMENT ("Assignment") is made as of March 2, 2006 by Sirius Laboratories, Inc., an Illinois corporation, whose principal office is located at 100 Fairway Drive, Suite 130, Vernon Hills, Illinois (the "Assignor"), and DUSA Pharmaceuticals, Inc., a New Jersey corporation, whose principal office is located at 25 Upton Drive, Wilmington, Massachusetts (the "Assignee").

WHEREAS, the parties have entered into a Merger Agreement, dated as of December 30, 2005, as amended by the First Amendment to the Merger Agreement, dated February 6, 2006 (as amended, the "Merger Agreement"), by and among the Assignor, the Assignee and the Principal Shareholders, pursuant to which Sirius Laboratories, Inc. shall be merged with and into a wholly owned subsidiary of the Assignee (the "Merger"), with such subsidiary being the surviving entity of the Merger. Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to such terms in the Merger Agreement.

WHEREAS, as part of the Merger, the Assignor has agreed to transfer and assign the Intellectual Property Rights to the Assignee and the parties have executed this Assignment for the purpose of confirming such transfer and assignment in a manner appropriate for recordation with the U.S. Patent and Trademark Office and other regulatory bodies;

NOW, THEREFORE, the parties hereto hereby agree as follows:

1. The Assignor hereby assigns and transfers to the Assignee all of the Assignor's rights, title, and interest in and to the Intellectual Property Rights as set forth on the attached EXHIBIT A hereto.

2. This Assignment shall allow the Assignee to file any applications applicable to the Intellectual Property Rights in its own name (but, in the case of patent applications, naming the proper inventor(s) as such) in all countries of the world (where permissible). For purposes of clarification, the rights assigned hereby include, without limitation, all of the Assignor's right to sue and recover for any past, present, and future infringement or unauthorized use of any right or interest in the Intellectual Property Rights.

3. The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue to and in the name of the Assignee all U.S. patents and U.S. trademark registrations that may be granted within the Intellectual Property Rights, as applicable.

4. The Assignor agrees to execute any further lawful documents and take any other actions that the Assignee might consider necessary or appropriate to fully protect and vest in the Assignee the assigned rights and interests in the Intellectual Property Rights and to assist the Assignee in the registration, maintenance, perfection, and enforcement of any of the Intellectual Property Rights.

IN WITNESS WHEREOF, this Assignment has been duly executed, sealed and delivered by an authorized officer of the Assignor as of the day and year first above written.

SIRIUS LABORATORIES, INC.

By: Frank R. Pollard

Name: Frank R. Pollard

Title: Vice Chairman

STATE OF ILLINOIS)
) SS
COUNTY OF LAKE)

On this the 27th day of February, 2006, before me, personally appeared Frank R. Pollard who, being by me duly sworn, did depose and say that he is the Vice Chairman of Sirius Laboratories, Inc., the corporation described in and which executed the above instrument, and that he as such Vice Chairman, being authorized to do so, executed the foregoing instrument for the purposes therein contained, by signing the name of the corporation by himself as Vice Chairman and attorney-in-fact.

Melanie A. Turner
Notary Public

My commission expires:

March 18, 2010




EXHIBIT A

[INCORPORATE FINAL VERSION OF SCHEDULE 3.9(a)]

SCHEDULE 3.9(a)

INTELLECTUAL PROPERTY RIGHTS

(i) Registered patents and patent applications

Patent Title	Country	Filing Date	Assignee	Filing #	Patent #	Issue Date	Expiration Date
Method of Treating Acne Vulgaris and Composition	USA	05/02/01	Sirius Laboratories	09/847,151	6,740,330	05/25/04	05/02/21
Sodium sulfacetamide Gel Skin Treatment Formulation and Method of Making Same	USA	12/06/02	Sirius Laboratories	10/313,400 Non-final rejection for pending claims 1-17 rec'd 11/16/05.	Pending	Pending	Pending
Compositions and Methods for Treating Inflammatory, Vascular and Infectious Cutaneous Conditions	USA	12/06/02	Sirius Laboratories	10/313,164 Non-final rejection for claims 1-4, 6 and 10 rec'd 10/19/05.	Pending	Pending	Pending
Sodium Sulfacetamide Gel Skin Cleanser and Method for Making Same	USA	12/06/02	Sirius Laboratories	10/313,805 Non-final rejection for pending claims 1-12 rec'd 11/9/05.	Pending	Pending	Pending
Oral Composition and Method for the Treatment of Inflammatory Cutaneous Disorders	USA	12/06/02	Sirius Laboratories	10/313,165	6,979,468	12/27/05	12/27/25
Methods and Composition for Treatment	USA	01/29/04	Sirius Laboratories	10/767,106	Pending	Pending	Pending




of Acne Vulgaris and Acne Rosacea							
Applicator Device Design	USA	1/12/06	Sirius Laboratories	29/251,796	Pending	Pending	Pending

(ii) Registered trademarks and applications for registration of trademarks

Trademark	Country of Filing	Description of Goods or Services	Registration or Application #	Date of Issue
AVAR [®]	USA	Pharmaceutical product for human use in dermatological disorders, namely, a topically applied treatment for acne, in Class 5	Reg. No. 2,990,223	08/30/2005
AVAR Cleanser [®]	USA	Pharmaceutical preparations for human use in dermatological disorders, namely, a topically applied treatment for acne, in Class 5	Reg. No. 2,961,496	06/07/2005
AVAR Green [®]	USA	Pharmaceutical preparation for human use in dermatological disorders, namely, a topically applied treatment for acne, in Class 5	Reg. No. 2,978,865	07/26/2005
AVAR-e [®]	USA	Pharmaceutical preparations for human use in dermatological disorders, namely, a topically applied treatment for acne, in Class 5	Reg. No. 2,974,225	07/19/0005
AVAR-e Green [®]	USA	Pharmaceutical preparations for human use in dermatological disorders, namely, a topically applied treatment for acne, in Class 5	Reg. No. 2,962,635	06/14/2005
Bacne [™]	USA	Pharmaceutical preparation for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,850	Pending
BacnePac [™]	USA	Pharmaceutical preparation for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,855	Pending
BacPac [™]	USA	Pharmaceutical preparation for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,843	Pending
BenNic [™]	USA	Pharmaceutical product for human use in allergic and dermatologic disorders, in Class 5	Serial No. 78-440,569	Pending
BenzoBac	USA	Pharmaceutical preparation for	Serial No. 78-734,830	Pending


D. C. Kelly, Jr.
Mark R. Pollard

EXECUTION COPY

		treatment of skin and allergic disorders, in Class 5		
ClindaBac™	USA	Pharmaceutical preparation for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,820	Pending
EasyReach™	USA	Pharmaceutical preparation applicator for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,867	Pending
ExtenDerm™	USA	Pharmaceutical preparation applicator for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,864	Pending
BPOBac™	USA	Pharmaceutical preparation for treatment of skin and allergic disorders	Serial No. 78-734848	Pending
ATOPLEX™	USA	Topically applied pharmaceutical preparation for the treatment of dermatological disorders	Serial No. 78-108825	Pending
ReachEase™	USA	Pharmaceutical preparation applicator for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,869	Pending
TretiBac™	USA	Pharmaceutical preparation for treatment of skin and allergic disorders, in Class 5	Serial No. 78-734,838	Pending
Meted®	USA	Medicated hair shampoo	Reg. No. 1,419,732	12/09/1986
Nicomide®	USA	Pharmaceutical preparations for human use in allergic and dermatological disorders, in Class 5	Reg. No. 2,592,990	07/09/2002
Nicomide-T®	USA	Pharmaceutical preparations for human use in allergic and skin disorders, in Class 5	Reg. No. 2,892,079	08/02/2005
PsoriaCap®	USA	Pharmaceutical preparations for human use in allergic and skin disorders, in Class 5	Reg. No. 2,760,258	09/02/2003
Psoriatec®	USA	Pharmaceutical preparations for human use in allergic and dermatological disorders, in Class 5	Reg. No. 2,780,636	11/04/2003
Sirius Laboratories, Inc.®	USA	Pharmaceutical preparations for the treatment of dermatological diseases in Class 5	Reg. No. 2,817,708	02/24/2004

(iii) Registered copyrights and applications for registration of copyrights

None.



(iv) **Common law trademarks, service marks, trade names, slogans and trade dress**

Sirius maintains Intellectual Property rights under unregistered logos, the artwork for which has been provided to DUSA.

(v) **License agreements pursuant to which Sirius has outstanding Intellectual Property rights to which Sirius is obligated to pay royalties**

1. 2006 Micanol License Agreement, dated January 30, 2006, by and between Sirius and Winston Laboratories, Inc.
2. Sale and Purchase Agreement, dated December 18, 2002, by and between Sirius and Elorac Limited;
3. Rights under Supply Agreement, dated October 21, 2005, by and between Sirius and L. Perrigo Company;
4. Rights under Development, License and Supply Agreement, dated June 13, 2005, by and between Sirius and Altana Inc.

(vi) **License agreements pursuant to which Sirius has outstanding Intellectual Property rights to which Sirius is entitled to receive royalties**

None.

D. G. Pollard
Mark R. Pollard